(firstQuint)Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs.

 Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation.

 This is single-center, open-label, prospective study of telmisartan for the prevention of acute GVHD in approximately 60 subjects undergoing allogeneic HCT for treatment of a hematologic malignancy.

 Subjects will receive 160 mg Micardis brand telmisartan once daily, starting 2 days prior to HCT (day -2).

 Once the patient is discharged post-HCT, treatment will continue through Day +98 post-HCT for a total of 101 days.

 After treatment discontinuation on or before day +98 post-HCT, subjects will be followed for up to 6 months for primary and secondary endpoints.

.

 Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs.

 Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation@highlight

This is single-center, open-label, prospective study of telmisartan for the prevention of acute GVHD in approximately 60 subjects undergoing allogeneic HCT for treatment of a hematologic malignancy.

